Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
This article was originally published in The Tan Sheet
Executive Summary
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.